Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sargent

Showing results (381-390 of 433) with videos related to

Pageof 44
Sort By:
Pharmacogenetics and Genomics|December 15, 2015
Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)Adam M Lee, Qian Shi, Steven R Alberts, et al.
CA: a Cancer Journal for Clinicians|January 20, 2016
American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicineMichael W Kattan, Kenneth R Hess, Mahul B Amin, et al.
Journal of the National Cancer Institute|June 14, 2014
Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147Wilson I Gonsalves, Michelle R Mahoney, Daniel J Sargent, et al.
Archives of Pathology & Laboratory Medicine|July 11, 2000
Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999C C Compton, L P Fielding, L J Burgart, et al.
Journal of the National Cancer Institute|August 5, 1999
Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancersK C Halling, A J French, S K McDonnell, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2020
CSTI-300 (SMP-100); a Novel 5-HT<sub>3</sub> Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome or Carcinoid SyndromeAlexander Roberts, Gillian Grafton, Andrew D Powell, et al.
NPJ Precision Oncology|February 26, 2026
FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AMLSanthosh Kumar Pasupuleti, Sravanti Rangaraju, Justin Layer, et al.
JCO Precision Oncology|September 14, 2020
Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 TrialsAziz Zaanan, Qian Shi, Julien Taieb, et al.
JAMA Oncology|October 7, 2017
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical TrialsAziz Zaanan, Qian Shi, Julien Taieb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregationSharlene Gill, Noralane M Lindor, Lawrence J Burgart, et al.
Pageof 44

Showing results (381-390 of 433) with videos related to

Sort By:
Pageof 44
Pharmacogenetics and Genomics|December 15, 2015
Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)Adam M Lee, Qian Shi, Steven R Alberts, et al.
CA: a Cancer Journal for Clinicians|January 20, 2016
American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicineMichael W Kattan, Kenneth R Hess, Mahul B Amin, et al.
Journal of the National Cancer Institute|June 14, 2014
Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147Wilson I Gonsalves, Michelle R Mahoney, Daniel J Sargent, et al.
Archives of Pathology & Laboratory Medicine|July 11, 2000
Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999C C Compton, L P Fielding, L J Burgart, et al.
Journal of the National Cancer Institute|August 5, 1999
Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancersK C Halling, A J French, S K McDonnell, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2020
CSTI-300 (SMP-100); a Novel 5-HT<sub>3</sub> Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome or Carcinoid SyndromeAlexander Roberts, Gillian Grafton, Andrew D Powell, et al.
NPJ Precision Oncology|February 26, 2026
FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AMLSanthosh Kumar Pasupuleti, Sravanti Rangaraju, Justin Layer, et al.
JCO Precision Oncology|September 14, 2020
Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 TrialsAziz Zaanan, Qian Shi, Julien Taieb, et al.
JAMA Oncology|October 7, 2017
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical TrialsAziz Zaanan, Qian Shi, Julien Taieb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregationSharlene Gill, Noralane M Lindor, Lawrence J Burgart, et al.
Pageof 44